Register Login

METAVIA INC. (MTVA)

SymbolMTVA
NameMETAVIA INC.
SectorHEALTH CARE
RegionNorth America
IndustryBiotechnology: Pharmaceutical Preparations
Address545 CONCORD AVENUE,SUITE 210, CAMBRIDGE, Massachusetts, 02138, United States
Telephone+1 857 702-9600
Fax—
Email—
Websitehttps://www.metaviatx.com
IncorporationUNDEFINED
Incorporated On—
Employees—
Fiscal Year—
Public Since—
ExchangesNASDAQ
Auditor—
Audit StatusNOT PROVIDED
Reporting Status—
CIK0001638287
Description

MetaVia Inc., formerly NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus resulting in body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes.

Additional info from NASDAQ:
MetaVia Inc., formerly NeuroBo Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. It is developing DA-1726 for the treatment of obesity, and is developing DA-1241 for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel oxyntomodulin (OXM) analogue that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) dual agonist. OXM is a naturally-occurring gut hormone that activates GLP1R and GCGR, thereby decreasing food intake while increasing energy expenditure, thus resulting in body weight loss compared to selective GLP1R agonists. DA-1241 is a novel G-Protein-Coupled Receptor 119 (GPR119) agonist with development optionality as a standalone and/or combination therapy for both MASH and type 2 diabetes.

2026-06-08 22:33

Director Tursi James Patrick 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071475

Read more
2026-06-08 22:33

Director STRICKLAND D GORDON 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071474

Read more
2026-06-08 22:32

Director Salsbury Michael 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071473

Read more
2026-06-08 22:31

Director GROVES JASON L 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071472

Read more
2026-06-08 22:30

Director KOVEN ANDREW I 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071471

Read more
2026-06-08 22:29

Director Glickman Mark A 🟢 acquired 17.2K shares of MetaVia Inc. (MTVA) Transaction Date: Jun 08, 2026 | Filing ID: 071469

Read more
2026-06-08 20:00

(99% Neutral) METAVIA INC. (MTVA) Announces Executive Changes

Read more
2026-06-08 13:01

(90% Positive) METAVIA INC. (MTVA) Provides Update on results for a Preclinical T2D Model​CAMBRIDGE

Read more
2026-06-04 12:31

MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference

Read more
2026-05-27 13:01

(90% Positive) METAVIA INC. (MTVA) Announces Clinical Development Update

Read more